These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22850535)

  • 1. Myasthenia gravis: helping patients have better outcomes.
    Weeks BH
    Nurse Pract; 2012 Sep; 37(9):30-6; Quiz 36-7. PubMed ID: 22850535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of therapeutic options used for myasthenia gravis.
    Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
    Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis.
    Kothari MJ
    J Am Osteopath Assoc; 2004 Sep; 104(9):377-84. PubMed ID: 15452103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis].
    Tatay J; Díez-Tejedor E; Frank A; Tejada J; Marrero C; Barreiro P
    Rev Neurol; 1997 Sep; 25(145):1402-6. PubMed ID: 9377299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of myasthenia gravis.
    Saperstein DS; Barohn RJ
    Semin Neurol; 2004 Mar; 24(1):41-8. PubMed ID: 15229791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital.
    Pittayanon R; Treeprasertsuk S; Phanthumchinda K
    J Med Assoc Thai; 2009 Apr; 92(4):478-82. PubMed ID: 19374297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bringing life into focus. An overview of myasthenia gravis.
    Johnson J
    Adv Nurse Pract; 2008 Mar; 16(3):69-73, 82-3. PubMed ID: 19999509
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
    Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
    Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to immunomodulation in patients with myasthenia gravis.
    Katzberg HD; Barnett C; Bril V
    Muscle Nerve; 2012 May; 45(5):648-52. PubMed ID: 22499090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis.
    O'carroll P; Bertorini TE; Jacob G; Mitchell CW; Graff J
    J Clin Neuromuscul Dis; 2009 Dec; 11(2):69-71. PubMed ID: 19955986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis.
    Ortiz-Salas P; Velez-Van-Meerbeke A; Galvis-Gomez CA; Rodriguez Q JH
    J Clin Neuromuscul Dis; 2016 Sep; 18(1):1-11. PubMed ID: 27552383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.
    Jensen P; Bril V
    J Clin Neuromuscul Dis; 2008 Mar; 9(3):352-5. PubMed ID: 18344718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the evidence base for therapeutics in myasthenia gravis.
    Miller RG; Barohn RJ; Dubinsky R
    Ann Neurol; 2010 Dec; 68(6):776-7. PubMed ID: 21194147
    [No Abstract]   [Full Text] [Related]  

  • 15. The treatment of patients with myasthenia gravis.
    Sanders DB; Scoppetta C
    Neurol Clin; 1994 May; 12(2):343-68. PubMed ID: 8041346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.
    Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB
    JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia].
    Pérez Nellar J; Domínguez AM; Llorens-Figueroa JA; Ferrá-Betancourt A; Pardo A; Quiala M; Gali Z
    Rev Neurol; 2001 Sep 1-15; 33(5):413-6. PubMed ID: 11727205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis: effect of immunoactive therapies.
    Fornádi L; Horváth R; Bárdosi Z; Szobor A
    Acta Med Hung; 1994; 50(1-2):83-92. PubMed ID: 7638045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis: clinical, immunological, and therapeutic advances.
    Romi F; Gilhus NE; Aarli JA
    Acta Neurol Scand; 2005 Feb; 111(2):134-41. PubMed ID: 15644074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.